Research & Development
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
18 November 2026 -

Inhibrx Biosciences Inc (Nasdaq:INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, announced on Tuesday updated clinical data from the Phase 1/2 expansion study evaluating ozekibart (INBRX-109), an investigational tetravalent death receptor 5 (DR5) agonist, in combination with irinotecan and temozolomide (IRI/TMZ) in patients with relapsed or refractory Ewing sarcoma.

The data will be presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting.

As of the data cutoff on 18 September, 60 patients (including 9 adolescent patients) were enrolled and treated with ozekibart plus IRI/TMZ, with 22 patients remaining on active treatment. Among the 51 response-evaluable patients, the combination demonstrated an overall response rate (ORR) of 62.7%, comprising 2 complete responses (CRs) and 30 partial responses (PRs). A total of 84.3% of response-evaluable patients (43/51) experienced measurable reduction in tumour size from baseline. An additional 12 patients achieved stable disease (SD), resulting in a Disease Control Rate (DCR) of 86.3%.

The median progression free survival (mPFS) was 6.0 months. Durable clinical benefit exceeding 6 months was observed in 18 patients (1 CR, 1 SD, 16 PRs), including 1 patient maintaining an ongoing PR for more than 2 years. At the cutoff date, 14 response-evaluable patients remained progression-free, including 2 patients with a PFS duration exceeding 12 months.

According to the company, these data represent a meaningful improvement over historical benchmarks, such as irinotecan and temozolomide alone in relapsed or refractory Ewing sarcoma, which typically yield an ORR of approximately 15% to 30% and mPFS of around 3 to 4 months.

Inhibrx said that the combination continued to demonstrate an acceptable and manageable safety profile consistent with the known cytotoxic toxicities of IRI/TMZ and DR5 agonism, with no evidence of unexpected cumulative hepatotoxicity.

The FDA has accepted for filing the biologics license application for the potential approval of ozekibart in conventional chondrosarcoma.

Login
Username:

Password: